Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30731238 | 1.00 | NCEH1 (0.50) | NCEH1TSHRCYP3A4HSP90AA1CRHBP | |
| SCHEMBL26933718 | 0.83 | HSP90AA1 (0.38) | NCEH1TSHRCYP3A4HSP90AA1CRHBP | |
| SCHEMBL24150446 | 0.83 | S1PR4 (0.36) | NCEH1MAPTSMN1; SMN2LMNAHPGD | |
| SCHEMBL26933457 | 0.82 | HSP90AA1 (0.42) | NCEH1TSHRCYP3A4HSP90AA1CRHBP | |
| SCHEMBL16239172 | 0.82 | HASPIN (0.43) | NCEH1MAPTLMNAHTTPDE4A | |
| SCHEMBL8623033 | 0.81 | NCEH1 (0.57) | NCEH1TSHRCYP3A4HSP90AA1CRHBP | |
| SCHEMBL6361624 | 0.81 | HNF4A (0.43) | MAPTLMNAHPGDALDH1A1PTPN1 | |
| SCHEMBL2312202 | 0.80 | CASP6 (0.38) | NCEH1TSHRMAPTSMN1; SMN2LMNA | |
| SCHEMBL635407 | 0.79 | MAPT (0.49) | TSHRCYP3A4NPC1RAB9AMAPT | |
| SCHEMBL29560409 | 0.79 | MAPT (0.49) | TSHRCYP3A4NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360143-A1 | COMPOSITIONS AND METHODS FOR PHARMACOLOGIC TREATMENT OF STROKE AND MYOCARDIAL ISCHEMIA REPERFUSION INJURY | UNIV CONNECTICUT (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4536215-A2 | COMPOSITIONS AND METHODS FOR PHARMACOLOGIC TREATMENT OF STROKE AND MYOCARDIAL ISCHEMIA REPERFUSION INJURY | University of Connecticut (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-12-19 | — | — | US | disclosed |
| US-12116351-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-10-15 | — | — | US | disclosed |
| WO-2023239767-A2 | COMPOSITIONS AND METHODS FOR PHARMACOLOGIC TREATMENT OF STROKE AND MYOCARDIAL ISCHEMIA REPERFUSION INJURY | UNIVERSITY OF CONNECTICUT (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20220380322-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-12-01 | — | — | US | disclosed |
| US-11434207-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-09-06 | — | — | US | disclosed |
| EP-3020717-B1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO (JP) | 2021-12-15 | — | — | EP | disclosed |
| CN-108863959-B | P2X4 receptor antagonists | 日本化学药品株式会社 | 2021-11-30 | — | — | CN | disclosed |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2020-07-16 | — | — | US | disclosed |
| US-20130281441-A1 | DIAZEPINEDIONE DERIVATIVE | NIPPON CHEMIPHAR CO (JP) | 2013-10-24 | — | — | US | disclosed |
| EP-2631229-A1 | P2X4 RECEPTOR ANTAGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2013-08-28 | — | — | EP | disclosed |
| EP-2397480-B1 | DIAZEPINEDIONE DERIVATIVE | NIPPON CHEMIPHAR CO (JP) | 2013-08-14 | — | — | EP | disclosed |
| CN-103237794-A | P2X4Receptor antagonists | NIPPONCHEMIPHAR CO LTD | 2013-08-07 | — | — | CN | disclosed |
| US-20130178625-A1 | P 2 X 4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2013-07-11 | — | — | US | disclosed |
| US-8470814-B2 | Diazepinedione derivative | NIPPON CHEMIPHAR CO., LTD. (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20110319610-A1 | DIAZEPINEDIONE DERIVATIVE | NIPPON CHEMIPHAR CO., LTD. (JP) | 2011-12-29 | — | — | US | disclosed |
| EP-2397480-A1 | DIAZEPINEDIONE DERIVATIVE | Nippon Chemiphar Co., Ltd. (JP) | 2011-12-21 | — | — | EP | disclosed |
| EP-0696289-B1 | BENZO[F]QUINOXALINDIONE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN DRUGS | SCHERING AG (DE) | 1997-03-12 | — | — | EP | disclosed |
| WO-1994025470-A1 | BENZO[F]QUINOXALINDIONE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN DRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178625-A1 | P 2 X 4 RECEPTOR ANTAGONIST | P2RX4, P2RX2, P2RY4 | NCEH1 2192/4885TSHR 540/4885CYP3A4 405/4885 |
| US-20220380322-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | NCEH1 1864/4885TSHR 584/4885CYP3A4 1142/4885 |
| US-20130281441-A1 | DIAZEPINEDIONE DERIVATIVE | P2RX7, P2RX4, P2RX3 | NCEH1 3287/4885TSHR 303/4885CYP3A4 466/4885 |
| US-20250360143-A1 | COMPOSITIONS AND METHODS FOR PHARMACOLOGIC TREATMENT OF STROKE AND MYOCARDIAL ISCHEMIA REPERFUSION INJURY | PLAT, SERPINE1, SERPINC1 | NCEH1 298/4885TSHR 817/4885CYP3A4 3466/4885 |
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | NCEH1 2070/4885TSHR 614/4885CYP3A4 1082/4885 |
| US-20110319610-A1 | DIAZEPINEDIONE DERIVATIVE | P2RX7, P2RX4, P2RX3 | NCEH1 3287/4885TSHR 303/4885CYP3A4 466/4885 |
| US-12116351-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | NCEH1 1864/4885TSHR 584/4885CYP3A4 1142/4885 |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | NCEH1 1864/4885TSHR 584/4885CYP3A4 1142/4885 |
| US-11434207-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | NCEH1 1864/4885TSHR 584/4885CYP3A4 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.